MactierR.A., van StoneJ., CoxA., van StoneM., TwardowskiZ.Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcaemia.Clin Nephrol.1987; 28: 222–6.
2.
CunninghamJ., BeerJ., ColdwellR.D., NoonanK., SawyerN., MakinH.L.J.Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol.Nephral Dial Transplant.1992; 7: 63–8.
3.
ArmstrongA., BeerJ., NoonanK., CunninghamJ.Reduced calcium dialysate in CAPD patients: Efficacy and limitations.Nephral Dial Transplant.1997; 12: 1223–8.
4.
ChertowJ.M., BurkeS.K., GoldbergD., BleyerA.J., GarrattB.N., DomotoD.T.Poly[allylamine hydrochloride] (RenaGel) [RG] with and without supplemental calcium [C] for hyperphosphatemia [hp] in ESRD [Abstract].J Am Sac Nephral.1997; 8: 549A.
5.
DelmezJ.A., SlatopolskyE.Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease.Am J Kidney Dis.1992; 19: 303–17.
6.
ChertowJ.M., BurkeS.K., LazarusJ.M., StenzelK.H., WomboltD., GoldbergD.Poly[allylamine hydrochloride] (RenaGel): A non calcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.Am J Kidney Dis.1997; 29: 66–71.
7.
DewberryK., FoxJ.S., StewartJ., MurrayJ.R., HutchisonA.J.Lanthanum carbonate: A novel non calcium containing phosphate binder [Abstract].J Am Sac Nephral.1997; 8: 549A.
8.
MallucheH., FaugereM-CRenal bone disease 1990: An unmet challenge for the nephrologist.Kidney Int.1990; 38: 193–221.
9.
CunninghamJ.Parathyroid pathophysiology in uraemia.Nephral Dial Transplant.1996; 11(Suppl 3): 106–10.
10.
FukadaN., TanakaH., ToninayoY., FukayawaM., KurakawaK., SeinoY.Decreased 1,25-dihydroxy vitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.J Clin Invest.1993; 92: 1436–42.
11.
GogusevJ., DuchambonP., HoryB., GiovaniniM., SarfatiE., DruekeT.B.Decreased expression of calcium receptor in parathyroid gland tissue of patients with primary or secondary uremic hyperparathyroidism.Kidney Int.1997; 51: 328–36.
12.
WangM., HerczG., SherrardD.J., MaloneyN.A., SegreG.V., PeyY.Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.Am J Kidney Dis.1995; 26: 836–44.
13.
SherrardD.J., HerczG., PeyY., MaloneyN.A., GreenwoodC., ManuelA.The spectrum of bone disease in end-stage renal failure -An evolving disorder.Kidney Int.1993; 43: 436–42.
14.
BikleD.D.Biochemical markers in the assessment of bone disease.Am J Med.1997; 103: 427–36.
15.
CoburnJ.W., FrazaoJ.Calcitriol in the management of renal osteodystrophy.Semin Dial.1996; 9: 316–26.
16.
LefebvreA., de VerngoulM.C., GuerisJ., GoldfarbB., GrauletA.M., MorieuxC.Optimal correction of acidosis changes the progression of dialysis osteodystrophy.Kidney Int.1989; 36: 1112–18.
17.
AntonsenJ.E., SherrardD.J., AndressD.L.A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure.Kidney Int.1998; 53: 223–7.
